Insider Transactions in Q1 2024 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+13.99%
|
-
|
|
Mar 15
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+20.58%
|
-
|
|
Mar 15
2024
|
Matthew T. Wiley Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Mar 15
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+27.83%
|
-
|
|
Mar 15
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+22.28%
|
-
|
|
Mar 15
2024
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+28.76%
|
-
|
|
Mar 14
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+4.31%
|
-
|
|
Mar 14
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+7.49%
|
-
|
|
Mar 14
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+12.69%
|
-
|
|
Mar 14
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,610
+6.97%
|
-
|
|
Mar 14
2024
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+13.55%
|
-
|